Clinical Trials Logo

Recurrent Glioblastoma clinical trials

View clinical trials related to Recurrent Glioblastoma.

Filter by:

NCT ID: NCT03896568 Recruiting - Clinical trials for Recurrent Glioblastoma

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Start date: February 12, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.

NCT ID: NCT03749187 Recruiting - Glioblastoma Clinical Trials

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

PNOC017
Start date: April 3, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

NCT ID: NCT03115333 Recruiting - Clinical trials for Recurrent Glioblastoma

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Start date: July 25, 2017
Phase: N/A
Study type: Interventional

This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.

NCT ID: NCT03107780 Recruiting - Glioblastoma Clinical Trials

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Start date: July 9, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.